BLC
MRNA icon

Brown, Lisle/Cummings’s Moderna MRNA Stock Holding History

Brown, Lisle/Cummings’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Hold
375
– – 0.01% 468
2026
Q1 		$19.1K Hold
375
– – ﹤0.01% 480
2025
Q4 		$11.1K Sell
375
-100
-21% -$2.72K ﹤0.01% 491
2025
Q3 		$12.3K Hold
475
– – ﹤0.01% 481
2025
Q2 		$13.1K Hold
475
– – ﹤0.01% 472
2025
Q1 		$13.5K Hold
475
– – ﹤0.01% 456
2024
Q4 		$19.8K Sell
475
-1,160
-71% -$55.4K 0.01% 422
2024
Q3 		$109K Buy
1,635
+100
+7% +$9.18K 0.03% 255
2024
Q2 		$182K Hold
1,535
– – 0.06% 209
2024
Q1 		$164K Hold
1,535
– – 0.06% 209
2023
Q4 		$153K Hold
1,535
– – 0.06% 208
2023
Q3 		$159K Hold
1,535
– – 0.07% 198
2023
Q2 		$187K Hold
1,535
– – 0.08% 186
2023
Q1 		$236K Buy
1,535
+1,000
+187% +$165K 0.12% 159
2022
Q4 		$96.1K Hold
535
– – 0.05% 212
2022
Q3 		$63.3K Buy
535
+150
+39% +$22.8K 0.04% 237
2022
Q2 		$55K Hold
385
– – 0.03% 252
2022
Q1 		$66.3K Hold
385
– – 0.03% 241
2021
Q4 		$97.8K Buy
+385
New +$113K 0.05% 209

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Brown, Lisle/Cummings's MRNA Position: Q2 2026 in Review

Brown, Lisle/Cummings held its Moderna (MRNA) position steady in Q2 2026 at 375 shares worth $26.3K. The position accounts for 0.01% of the portfolio, ranked #468.

Brown, Lisle/Cummings first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. The position peaked at $236K in Q1 2023. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Brown, Lisle/Cummings held 375 shares of Moderna worth $26.3K as of Q2 2026.
  • Brown, Lisle/Cummings left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #468 holding.
  • Brown, Lisle/Cummings first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
  • Brown, Lisle/Cummings's Moderna position peaked at $236K in Q1 2023.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.